Apelin and its ratio to lipid factors are associated with cardiovascular diseases: A systematic review and meta-analysis.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
1
8
2022
pubmed:
2
8
2022
medline:
4
8
2022
Statut:
epublish
Résumé
The present systematic review and meta-analysis aimed to ascertain if the circulating levels of apelin, as an important regulator of the cardiovascular homeostasis, differ in patients with cardiovascular diseases (CVDs) and controls. A comprehensive search was performed in electronic databases including PubMed, Scopus, EMBASE, and Web of Science to identify the studies addressing apelin in CVD up to April 5, 2021. Due to the presence of different units to measure the circulating levels of apelin across the included studies, they expressed the standardized mean difference (SMD) and their 95% confidence interval (CI) as summary effect size. A random-effects model comprising DerSimonian and Laird method was used to pool SMDs. Twenty-four articles (30 studies) comprised of 1793 cases and 1416 controls were included. Pooled results obtained through random-effects model indicated that apelin concentrations in the cases' blood samples were significantly lower than those of the control groups (SMD = -0.72, 95% CI: -1.25, -0.18, P = 0.009; I2 = 97.3%, P<0.001). New combined biomarkers showed a significant decrease in SMD of apelin/high-density lipoprotein cholesterol (apelin/HDL-C) ratio [-5.17; 95% CI, -8.72, -1.63, P = 0.000; I2 = 99.0%], apelin/low-density lipoprotein cholesterol (apelin/LDL-C) ratio [-4.31; 95% CI, -6.08, -2.55, P = 0.000; I2 = 98.0%] and apelin/total cholesterol (apelin/TC) ratio [-17.30; 95% CI, -22.85, -11.76, P = 0.000; I2 = 99.1%]. However, no significant differences were found in the SMD of apelin/triacylglycerol (apelin/TG) ratio in cases with CVDs compared to the control group [-2.96; 95% CI, -7.41, 1.49, P = 0.000; I2 = 99.2%]. The association of apelin with CVDs is different based on the region and disease subtypes. These findings account for the possible usefulness of apelin as an additional biomarker in the diagnosis of CVD in diabetic patients and in the diagnosis of patients with CAD. Moreover, apelin/HDL-c, apelin/LDL-c, and apelin/TC ratios could be offered as diagnostic markers for CVD.
Sections du résumé
BACKGROUND
The present systematic review and meta-analysis aimed to ascertain if the circulating levels of apelin, as an important regulator of the cardiovascular homeostasis, differ in patients with cardiovascular diseases (CVDs) and controls.
METHODS
A comprehensive search was performed in electronic databases including PubMed, Scopus, EMBASE, and Web of Science to identify the studies addressing apelin in CVD up to April 5, 2021. Due to the presence of different units to measure the circulating levels of apelin across the included studies, they expressed the standardized mean difference (SMD) and their 95% confidence interval (CI) as summary effect size. A random-effects model comprising DerSimonian and Laird method was used to pool SMDs.
RESULTS
Twenty-four articles (30 studies) comprised of 1793 cases and 1416 controls were included. Pooled results obtained through random-effects model indicated that apelin concentrations in the cases' blood samples were significantly lower than those of the control groups (SMD = -0.72, 95% CI: -1.25, -0.18, P = 0.009; I2 = 97.3%, P<0.001). New combined biomarkers showed a significant decrease in SMD of apelin/high-density lipoprotein cholesterol (apelin/HDL-C) ratio [-5.17; 95% CI, -8.72, -1.63, P = 0.000; I2 = 99.0%], apelin/low-density lipoprotein cholesterol (apelin/LDL-C) ratio [-4.31; 95% CI, -6.08, -2.55, P = 0.000; I2 = 98.0%] and apelin/total cholesterol (apelin/TC) ratio [-17.30; 95% CI, -22.85, -11.76, P = 0.000; I2 = 99.1%]. However, no significant differences were found in the SMD of apelin/triacylglycerol (apelin/TG) ratio in cases with CVDs compared to the control group [-2.96; 95% CI, -7.41, 1.49, P = 0.000; I2 = 99.2%].
CONCLUSION
The association of apelin with CVDs is different based on the region and disease subtypes. These findings account for the possible usefulness of apelin as an additional biomarker in the diagnosis of CVD in diabetic patients and in the diagnosis of patients with CAD. Moreover, apelin/HDL-c, apelin/LDL-c, and apelin/TC ratios could be offered as diagnostic markers for CVD.
Identifiants
pubmed: 35913970
doi: 10.1371/journal.pone.0271899
pii: PONE-D-22-10262
pmc: PMC9342781
doi:
Substances chimiques
Apelin
0
Biomarkers
0
Cholesterol, HDL
0
Cholesterol, LDL
0
Triglycerides
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0271899Déclaration de conflit d'intérêts
I have read the journal’s policy and have no conflicts.
Références
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Pediatr Cardiol. 2018 Aug;39(6):1188-1193
pubmed: 29632960
Clin Chim Acta. 2018 Aug;483:241-248
pubmed: 29750964
J Endocrinol. 2013 Jan 02;216(1):T17-36
pubmed: 23160967
Regul Pept. 2007 May 3;140(3):178-84
pubmed: 17223209
Can J Physiol Pharmacol. 2018 Jan;96(1):38-44
pubmed: 28957639
Eur J Heart Fail. 2006 Jun;8(4):355-60
pubmed: 16464638
Eur J Heart Fail. 2008 Aug;10(8):725-32
pubmed: 18583184
Circ Res. 2002 Sep 6;91(5):434-40
pubmed: 12215493
Open Access Maced J Med Sci. 2018 Apr 04;6(4):613-617
pubmed: 29731925
Genet Mol Res. 2015 Jan 15;14(1):93-100
pubmed: 25729940
Hellenic J Cardiol. 2021 Jan-Feb;62(1):89-91
pubmed: 32387593
J Clin Endocrinol Metab. 2014 Sep;99(9):3093-102
pubmed: 24848708
J Am Coll Cardiol. 2006 Sep 19;48(6):1217-24
pubmed: 16979009
Endocrinology. 2011 Jan;152(1):59-68
pubmed: 21047945
BMC Oral Health. 2019 Aug 6;19(1):175
pubmed: 31387562
J Cardiovasc Med (Hagerstown). 2014 Aug;15(8):642-6
pubmed: 24933193
JRSM Cardiovasc Dis. 2017 Jan 01;6:2048004016687211
pubmed: 28286646
Life Sci. 2019 Sep 1;232:116645
pubmed: 31299236
Korean Circ J. 2015 Sep;45(5):386-90
pubmed: 26413106
Acta Cardiol Sin. 2020 May;36(3):216-222
pubmed: 32425436
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
JPEN J Parenter Enteral Nutr. 2008 Nov-Dec;32(6):638-44
pubmed: 18974244
J Cell Biochem. 2019 Jun;120(6):9159-9171
pubmed: 30548657
Eur J Heart Fail. 2007 Mar;9(3):306-9
pubmed: 16891152
PLoS One. 2013 Sep 06;8(9):e71041
pubmed: 24039710
Trends Biochem Sci. 2009 Oct;34(10):500-10
pubmed: 19729309
Congenit Heart Dis. 2019 Mar;14(2):256-263
pubmed: 30485657
Adv Med Sci. 2008;53(1):32-6
pubmed: 18635422
Medicine (Baltimore). 2018 Sep;97(39):e12580
pubmed: 30278567
Eur Heart J. 2006 Jan;27(2):222-6
pubmed: 16278229
Biochem Biophys Res Commun. 2003 Aug 29;308(3):480-5
pubmed: 12914775
J Pak Med Assoc. 2016 Mar;66(3):306-11
pubmed: 26968282
Transl Res. 2010 May;155(5):238-46
pubmed: 20403579
Int Heart J. 2014;55(3):204-12
pubmed: 24806385
Medicine (Baltimore). 2015 Jan;94(4):e449
pubmed: 25634182
Life Sci. 2018 Aug 15;207:525-531
pubmed: 29981321
Mol Cell Endocrinol. 2012 Oct 15;362(1-2):227-41
pubmed: 22842084
J Cell Mol Med. 2015 Jan;19(1):53-61
pubmed: 25311234
Circulation. 2010 Apr 27;121(16):1818-27
pubmed: 20385929
BMC Cardiovasc Disord. 2018 Dec 14;18(1):237
pubmed: 30547758
Am J Nephrol. 2006;26(2):121-6
pubmed: 16549903
J Mol Cell Cardiol. 2006 Nov;41(5):798-806
pubmed: 16919293
Int J Physiol Pathophysiol Pharmacol. 2015 Dec 25;7(4):165-71
pubmed: 27073592
Life Sci. 2018 Aug 15;207:166-171
pubmed: 29883719